Infectious Diseases (except HIV/AIDS)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection

1. Mayan Gilboa
2. Gili Regev-Yochay
3. Michal Mandelboim
4. Victoria Indenbaum
5. Keren Asraf
6. Ronen Fluss
7. Sharon Amit
8. Ella Mendelson
9. Ram Doolman
10. Arnon Afek
11. Laurence S. Freedman
12. Yitshak Kreiss
13. Yaniv Lustig

Reviewed by ScreenIT

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern

1. Chang Yi Wang
2. Kao-Pin Hwang
3. Hui-Kai Kuo
4. Be-Sheng Kuo
5. Hope Liu
6. Kuo-Liang Hou
7. Wan-Yu Tsai
8. Han-Chen Chiu
9. Yu-Hsin Ho
10. Jennifer Cheng
11. Min-Sheng Wang
12. Ya-Ting Yang
13. Po-Yen Chang
14. Yea-Huei Shen
15. Wen-Jiun Peng

Reviewed by ScreenIT

Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV

1. Cristina Venturini
2. Charlotte J. Houldcroft
3. Arina Lazareva
4. Fanny Wegner
5. Sofia Morfopoulou
6. Persis J. Amrolia
7. Zainab Golwala
8. Anupama Rao
9. Stephen D. Marks
10. Jacob Simmonds
11. Tetsushi Yoshikawa
12. Paul J. Farrell
13. Jeffrey I. Cohen
14. Austen J. Worth
15. Judith Breuer

• Curated by eLife

  Evaluation Summary:

  The author present a large amount of sequencing data of EBV present in a variety of individuals, including a few with the interesting and unusual disease manifestation known as Chronic Active EBV (CAEV). The data show that there is a great deal of heterogeneity in the EBV genomes among people and overtime in some individuals, but the data do not reveal any particular mechanistic insights about the importance of this heterogeneity and the sample size is too small to warrant use of these deletions as therapeutic biomarkers.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #3 agreed to share their name with the authors.)

Reviewed by eLife

Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta

1. Daniel J. Grint
2. Kevin Wing
3. Hamish P. Gibbs
4. Stephen JW Evans
5. Elizabeth Williamson
6. Krishnan Bhaskaran
7. Helen I McDonald
8. Alex J. Walker
9. David Evans
10. George Hickman
11. Rohini Mathur
12. Anna Schultze
13. Christopher T Rentsch
14. John Tazare
15. Ian J Douglas
16. Helen J. Curtis
17. Caroline E Morton
18. Sebastian Bacon
19. Simon Davy
20. Brian MacKenna
21. Peter Inglesby
22. Richard Croker
23. John Parry
24. Frank Hester
25. Sam Harper
26. Nicholas J DeVito
27. Will Hulme
28. Chris Bates
29. Jonathon Cockburn
30. Amir Mehrkar
31. Ben Goldacre
32. Rosalind M. Eggo
33. Laurie Tomlinson

Reviewed by ScreenIT

SARS-CoV-2 outbreaks in secondary school settings in the Netherlands during fall 2020; silent circulation

1. Lotte Jonker
2. Kimberly J. Linde
3. Marieke L. A. de Hoog
4. Robin Sprado
5. Robin C. Huisman
6. Richard Molenkamp
7. Bas B. Oude Munnink
8. Wietske Dohmen
9. Dick J. J. Heederik
10. Dirk Eggink
11. Matthijs R. A. Welkers
12. Harry Vennema
13. Pieter L. A. Fraaij
14. Marion P. G. Koopmans
15. Inge M. Wouters
16. Patricia C. J. L. Bruijning-Verhagen

Reviewed by ScreenIT

An early return-to-work program for COVID-19 close contacts in healthcare during the Omicron wave in Japan

1. Hiroyuki Naruse
2. Yohei Doi
3. Mitsunaga Iwata
4. Kiyohito Ishikawa

Reviewed by ScreenIT

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru

1. Natalia Vargas-Herrera
2. Manuel Fernández-Navarro
3. Nestor E. Cabezudo
4. Percy Soto-Becerra
5. Gilmer Solís-Sánchez
6. Stefan Escobar-Agreda
7. Javier Silva-Valencia
8. Luis Pampa-Espinoza
9. Ricardo Bado-Pérez
10. Lely Solari
11. Roger V. Araujo-Castillo

Reviewed by ScreenIT

Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel

1. Lilac Tene
2. Gabriel Chodick
3. Noga Fallach
4. Wajeeha Ansari
5. Tal Distelman-Menachem
6. Yasmin Maor

Reviewed by ScreenIT

Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study

1. Chunmei Li
2. Ao Li
3. Hanfang Bi
4. Jun Hu
5. Fan Yang
6. Taicheng Zhou
7. Yupeng Liang
8. Wei Su
9. Tianpei Shi
10. Mei Yang
11. Rong Wang
12. Wanting Qin
13. Zumi Zhou
14. Jia Wei
15. Zhenwang Fu
16. Zijie Zhang

Reviewed by ScreenIT

Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study

1. Luther A. Bartelt
2. Alena J. Markmann
3. Bridget Nelson
4. Jessica Keys
5. Heather Root
6. Heather I. Henderson
7. JoAnn Kuruc
8. Caroline Baker
9. D. Ryan Bhowmik
10. Yixuan J. Hou
11. Lakshmanane Premkumar
12. Caleb Cornaby
13. John L. Schmitz
14. Susan Weiss
15. Yara Park
16. Ralph Baric
17. Aravinda M. de Silva
18. Anne Lachiewicz
19. Sonia Napravnik
20. David van Duin
21. David M. Margolis

Reviewed by ScreenIT